Nanoflex technology is a new class of material designed to optimize the wound bed environment and accelerate healing. Produced as a sterile powder, Altrazeal™ is unique in application and performance on a moist wound surface. When applied to a moist wound, the powder interacts with wound exudate and hydrates. Hydration with exudate causes the powder to aggregate irreversibly and form a moist wound dressing which conforms to the surface of a wound bed and seals the wound. The resulting material is neither a hydrogel dressing nor an amorphous hydrocolloid, but an engineered advanced material designed to provide specific properties to enhance wound healing.
Intellectual Property
Patent application and CIP filed covering Hydrogel Nanoparticle Aggregates and Injectable Aggregates.
Patent application filed related to formation of a wound dressing in situ.
Patent Application filed related to the formation of viscous gels for use as medical prosthesis.
Inventions:
Hydrogel nanoparticle aggregate formation is controlled by nanoparticle size, crosslinking, and zeta potential.
Injectable hydrogel nanoparticles that form permanent, erodible, or partially erodible aggregates with minimal surgical intervention.
Shape retentive hydrogel nanoparticle aggregates that allow controlled release of drugs or other molecules by particle size variations.
Wound dressings with or without actives are produced from nanoparticle powder on exuding wounds.
ULURU Inc. developed and commercializes Altrazeal™, a transforming powder dressing with proprietary Nanoflex™ technology, for the management of exuding wounds. Visit
www.altrazeal.com
for clinical case studies, patient testimonials, application guidelines, and much more…
